Skip to main content

Table 1 Dysregulated expression of lncRNAs and their potential clinical implications in ovarian cancer

From: Long non-coding RNAs in ovarian cancer

LncRNA Differential expression in ovarian carcinoma Clinical application References
HOTAIRa Up HOTAIR levels were positively correlated with the FIGO stage, histological grade of the tumor, lymph node metastasis. HOTAIR was an independent prognostic factor for OS and DFS in ovarian cancer patients [37, 38]
HOXA11-ASa Down in EOC High HOXA11-AS in SOC expression in tumor tissues was an independent predictor of poor PFS and OS [40, 41]
Up in SOC
Xista Down Reduced expression of Xist in patient samples was correlated with a shorter progression-free interval [43,44,45]
ANRILa Up Elevated ANRIL expression was positive correlated with advanced FIGO stage, high histological grade, lymph node metastasis. ANRIL was an independent prognostic factor for OS. [54, 55]
MEG3a Down No evidence [61, 62]
HOST2a Up No evidence [64]
FAL1a Up FAL1 occurred frequently in epithelial cancer and were associated with clinical outcomes in patients with ovarian cancer [65]
LSINCT5a Up No evidence [66]
ZNF300P1a Down No evidence [67]
TC1500845, TC0901107 Up No evidence [68]
TC0100223, TC0101686 Down No evidence
TC0101441a Up TC0101441 was an independent prognostic factor for OS in ERα-positive ovarian cancer
AB073614a Up 5-year OS in ovarian cancer patients with high expression of AB073614 was inferior to that with low expression [73]
ASAP1-IT1 Up High expression of ASAP1-IT1 and FAM215A were associated with favorable OS [74]
FAM215A Up
PVT1a Up Low expression levels of PVT1 and lnc-SERTAD2–3 exhibited longer PFS and OS. PVT1, lnc-SERTAD2–3 and hsa-miR-200c-3p simultaneously can stratify patients’ risk of relapse into three discrete classes, high risk, mixed and low risk [60]
lnc-SERTAD2–3 Up
RP11-284 N8.3.1 Down RP11-284 N8.3.1 and AC104699.1.1 significantly divide stages III and IV ovarian cancer patients into high- and low-risk groups and their increased expressions were associated with a decreased risk of survival [77]
AC104699.1.1 Down
AC005562.1, AC105760.2, EPB41L4A-AS1, MCM3AP-AS1 Up Potential candidates associated with stage progression in ovarian cancer and could classify patients into high-and low-risk subgroups with significantly different survival outcomes [81]
AC074117.10, MEG8, RP11-220I1.1, RP11-429 J17.2, RP11-618G20.1 Down
AC092214.10, CYP3A5, LEMD1, PART1, RNF157-AS1, RP11-532F12.5 Up No evidence [83]
AC010680.1, ADAMTS9-AS1, ADAMTS9-AS2, AK021537, AK125532, GRTP1-AS1, LEMD1-AS1, LOC386758, LOC729970, RP1–7814.1, RP11-597D13.9, LEMD1-AS1 Down
lnc-SOX4–1, lnc-HRCT1–1 Up Low expression levels of lnc-SOX4–1 and lnc-HRCT1–1 exhibited longer PFS and OS [60]
RUNX1-IT1, MALAT1 Up RUNX1-IT1, MALAT1, H19, HOTAIRM1, LOC100190986 and AL132709.8 were associated with OS and DFS [49]
H19a Majority expressed in benign, borderline and invasive SOC, but not in epithelial cells of the mucinous tumors
HOTAIRM1, LOC100190986, AL132709.8 Up
SPRY4-IT1 Up High lncRNA SPRY4-IT1 expression is an independent prognostic factor for PFS and OS [85]
BC037530, AK021924, AK094536, AK094536, BC062365 Up Higher expressions of lncRNAs BC037530, AK021924, AK094536, AK094536, BC062365 and lower expressions of lncRNAs BC004123 BC007937 were associated with ovarian cancer patients survival and can serve as an independent predictor apart from FIGO stage and patient grade [86]
BC004123, BC007937 Down
LOC100288181 Up High Lnc-OC1 expression was associated with poor prognosis of ovarian cancer patients [87]
DUXAP10 Up The overall survival of patients with ovarian cancer whose DUXAP10 was overexpressed was significantly lower than that in the DUXAP10 low expression group. Tumor stage in DUXAP10 high expression group was higher, and the tumor volume was larger. [88]
  1. a mechanism described in ovarian cancer